ArticleScientific reports2025
Overexpression of androgen receptor signalling transactivator lncRNAs PRNCR1 and PCGEM1 are associated with the increased risk of PCOS.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of the LncRNA PRNCR1/miR-642a-5p/SSTR3 CeRNA network and its diagnostic value in type 2 diabetes mellitus.Diabetology & metabolic syndrome · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PCOS, a common disorder in reproductive aged women, characterized by hyperandrogenism. Hyperandrogenism can be attributed to the hyperactive androgen receptor (AR). Androgen receptor mediated signalling involves the association of multiple coregulators and any aberrant activity of these factors may disrupt the normal transcriptional activity of AR and hence may act as contributing factors in pathophysiology of hyperandrogenic disorders. LncRNAs PRNCR1 and PCGEM1 act as AR coactivators. The study was aimed at determining the association of these lncRNAs with PCOS. A total of 178 participants including 105 PCOS cases and 73 controls were recruited. The Anthropometric, Metabolic and hormonal characteristics of the participants were determined. Total RNA was isolated and reverse transcribed into cDNA. Quantitative real-time PCR was done to study the expression pattern of lncRNAs. The association between different parameters with the expression of PRNCR1 and PCGEM1 was determined by correlation analysis. The expression levels of PRNCR1 (PRNCR1, 5.28 (1.29-9.14) versus 1.07 (0.05-3.18); P < 0.001) (PCGEM1, 3.08 (0.29-8.79) versus 1.70 (0.116-3.73); P < 0.001) were significantly higher in Women with PCOS compared to controls. Furthermore, lncRNA PRNCR1 showed a positive correlation with testosterone (P < 0.001). ROC analysis showed a strong diagnostic performance of lncRNA PRNCR1 Optimal Cut off (Youden's Index) = 3.23, AUC = 0.988 (95% CI = 0.976-0.99) and Sensitivity = 0.91, Specificity = 1.00 and for PCGEM1 Optimal Cut off (Youden's Index) = 2.02, AUC = 0.86 (95% CI = 0.81-0.92) and Sensitivity = 0.82, Specificity: 0.90. Our results demonstrated that overexpression of AR coactivator lncRNAs PRNCR1 and PCGEM1 are associated with an increased risk of PCOS in Kashmiri women. These lncRNAs may act as important factors for the hyperactivation of AR and subsequent overexpression of AR regulated genes and thus may contribute towards the pathogenesis of PCOS and its clinical manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.